Infants with Congenital Nephrotic Syndrome often present with symptoms within the first three months of life. Common signs include severe swelling (edema), particularly around the eyes, abdomen, and legs, due to fluid retention. Parents may notice frothy urine, which indicates high protein levels. Affected infants may also experience poor growth, frequent infections, and in some cases, respiratory difficulties due to fluid accumulation in the lungs.

Diagnosing CNS involves a combination of clinical evaluation, laboratory tests, and imaging studies. A pediatric nephrologist will typically order urine tests to check for protein levels and blood tests to assess kidney function and albumin levels. Genetic testing may be conducted to identify specific mutations associated with CNS. A kidney biopsy, where a small sample of kidney tissue is examined under a microscope, can provide further insights into the condition's nature and severity.

Treatment for Congenital Nephrotic Syndrome focuses on managing symptoms and preventing complications. This may include medications such as diuretics to reduce swelling, albumin infusions to maintain blood protein levels, and antibiotics to prevent infections. In severe cases, dialysis or kidney transplantation may be necessary. Nutritional support is also crucial to ensure adequate growth and development.

The prognosis for infants with CNS varies depending on the underlying cause and response to treatment. While some children may achieve partial remission with medical management, others may progress to end-stage kidney disease, requiring long-term dialysis or transplantation. Early diagnosis and intervention are critical in improving outcomes and quality of life.

Congenital Nephrotic Syndrome is primarily caused by genetic mutations that affect the structure and function of the kidneys' filtering units. The most common form, Finnish-type CNS, is linked to mutations in the NPHS1 gene, which encodes a protein called nephrin. Other genetic mutations, such as those in the NPHS2 and WT1 genes, can also lead to CNS. In rare cases, CNS may result from infections or other non-genetic factors.

CNS is a rare condition, with an estimated incidence of 1 in 50,000 live births. It is more prevalent in certain populations, such as those of Finnish descent, where the incidence is higher due to the prevalence of specific genetic mutations. Both males and females are equally affected by the disorder.

The pathophysiology of CNS involves defects in the glomerular filtration barrier, which is responsible for filtering blood and preventing the loss of proteins into the urine. Genetic mutations disrupt the normal function of proteins like nephrin, leading to increased permeability of the glomerular barrier. This results in significant protein loss, hypoalbuminemia, and subsequent edema.

Currently, there are no specific measures to prevent Congenital Nephrotic Syndrome, especially when it is caused by genetic mutations. However, genetic counseling can be beneficial for families with a history of CNS, helping them understand the risks and implications for future pregnancies. Prenatal testing may also be an option for at-risk families.

Congenital Nephrotic Syndrome is a rare genetic disorder affecting the kidneys, leading to significant protein loss and associated symptoms. Early diagnosis and management are crucial in improving outcomes. Treatment focuses on symptom management and may involve medications, nutritional support, and in severe cases, dialysis or transplantation. Genetic counseling is recommended for families with a history of CNS.

For families dealing with Congenital Nephrotic Syndrome, understanding the condition is vital. CNS is a rare kidney disorder that appears shortly after birth, causing symptoms like swelling and frothy urine due to protein loss. While it is primarily genetic, early diagnosis and treatment can help manage symptoms and improve quality of life. Families are encouraged to seek genetic counseling to understand the condition better and explore options for future pregnancies.